Zy Therapeutics
Zy Therapeutics is a biomedical company focused on developing disease-modifying therapies that target brain calcifications in rare central nervous system (CNS) disorders. The company is developing a reformulated small-molecule therapy optimized for brain delivery and improved bioavailability, with an emphasis on rare/orphan and pediatric populations and on partnering for clinical development and commercialization.
Industries
N/A
Products
Kamini (ZY-001)
A reformulated version of disodium etidronate optimized for brain delivery and improved bioavailability, developed as a disease-modifying therapy to target brain calcifications associated with rare CNS disorders.
Kamini (ZY-001)
A reformulated version of disodium etidronate optimized for brain delivery and improved bioavailability, developed as a disease-modifying therapy to target brain calcifications associated with rare CNS disorders.
Services
Co-development and partnership collaborations
Strategic collaborations and co-development partnerships to advance reformulated CNS therapies toward clinical development and commercialization.
Co-development and partnership collaborations
Strategic collaborations and co-development partnerships to advance reformulated CNS therapies toward clinical development and commercialization.
Expertise Areas
- Rare disease drug development
- CNS-targeted drug delivery
- Drug reformulation and repurposing
- Clinical program design and execution
Key Technologies
- Small-molecule reformulation
- Brain/CNS delivery optimization
- Bioavailability enhancement
- Drug repurposing strategies